Description

Product Description

Osteocalcin (30-43) Fragment is a biologically active peptide corresponding to amino acid residues 30 to 43 of the human Osteocalcin protein, a non-collagenous protein secreted by osteoblasts. Osteocalcin is one of the most abundant and functionally significant proteins in bone matrix, involved in calcium binding and regulation of bone mineralization. The 30–43 fragment represents a key domain often detected in human serum as a biochemical indicator of bone turnover and osteoblastic activity.

Scientific Background

Osteocalcin, also known as Bone Gla Protein (BGLAP), is synthesized by osteoblasts during bone formation and is regulated by vitamin D and vitamin K–dependent carboxylation. Its fragments, such as the Osteocalcin (30-43) Fragment, are released into circulation during bone remodeling processes, providing a measurable indicator of bone turnover. This makes it particularly useful in monitoring metabolic bone diseases, including osteoporosis, osteopenia, and renal osteodystrophy.

The (30-43) peptide region corresponds to a segment that retains calcium-binding and bone-matrix-association characteristics. Studies have demonstrated that this peptide fragment correlates with bone resorption and formation rates, serving as a reliable marker of skeletal metabolic activity. It is commonly used in clinical research for the evaluation of therapeutic interventions aimed at improving bone health or preventing bone loss.

Biological Relevance

The Osteocalcin (30-43) Fragment is an important circulating biomarker of bone metabolism and osteoblast activity. It reflects both the synthesis of new bone tissue and the resorption of old bone, thus providing a comprehensive picture of skeletal remodeling. Elevated or diminished levels of Osteocalcin fragments in serum are associated with metabolic bone disorders and can be modulated by hormonal changes, physical activity, or pharmacological treatments.

In experimental research, this peptide fragment has been used to:

• Quantify osteoblastic activity through immunoassays and HPLC analysis.

• Investigate vitamin D– and parathyroid hormone–regulated bone remodeling.

• Evaluate drug efficacy in osteoporosis treatment models.

• Study bone–metabolism–endocrine cross-talk involving energy regulation and insulin signaling.

By mimicking the endogenous Osteocalcin fragment, Osteocalcin (30-43) Fragment serves as a valuable reference molecule for both in vitro and in vivo experiments investigating bone health, mineral balance, and systemic energy metabolism.

Product Specifications

Mechanism of Action

1. Indicator of Bone Remodeling

Osteocalcin (30-43) Fragment originates from the cleavage of Osteocalcin during bone matrix turnover. This peptide fragment is released into circulation when osteoblasts and osteoclasts are active, thereby reflecting both bone formation and resorption rates. Measurement of this fragment provides a direct biochemical insight into skeletal metabolism.

2. Calcium and Hydroxyapatite Interaction

The Osteocalcin protein, rich in γ-carboxyglutamic acid residues, binds tightly to calcium and hydroxyapatite. Although the (30-43) fragment lacks the full Gla region, it retains partial calcium affinity, influencing its ability to reflect bone matrix association and release kinetics.

3. Endocrine Role in Energy Metabolism

Recent research suggests Osteocalcin fragments act as hormones, regulating insulin secretion and energy expenditure. The 30–43 fragment serves as a model molecule to study these effects and may reveal how skeletal-derived peptides influence systemic metabolism.

4. Diagnostic Biomarker

Osteocalcin (30-43) Fragment is a widely recognized biomarker in bone research. Its serum concentration correlates with bone mineral density, physical activity, and response to anabolic or antiresorptive drugs. It can be measured using ELISA or mass spectrometry-based assays for evaluating bone turnover.

5. Pharmacological and Clinical Research Utility

This peptide fragment is used to standardize biomarker assays, study osteoanabolic pathways, and assess bone metabolism in aging and postmenopausal populations. It also contributes to pharmacodynamic evaluations in the development of bone-forming agents.

Side Effects

Osteocalcin (30-43) Fragment is a research-use-only peptide with no reported cytotoxicity under laboratory conditions.
However, as a peptide material, the following should be noted:

• Low toxicity: Safe for in vitro and ex vivo applications.

• Possible peptide aggregation: May occur if improperly solubilized.

• Potential immunogenicity: Should be considered when using in animal studies.

• Laboratory handling: Use gloves, lab coats, and eye protection.

Disclaimer

This product is for research use only and not for human or veterinary administration.
Not intended for therapeutic, diagnostic, or food applications. Handle in accordance with good laboratory practices.

Keywords

Osteocalcin (30-43) Fragment; Bone turnover marker peptide; Bone Gla Protein fragment; Osteoblast biomarker; Osteocalcin-derived peptide; Bone metabolism research; Osteoporosis peptide standard; Human bone metabolism marker; Peptide biomarker for osteogenesis; Osteocalcin fragment analysis.

Shipping Guarantee

All peptides are shipped globally under temperature-controlled logistics with full insurance and customs clearance support.

Transaction Guarantee

We support T/T, PayPal, and cryptocurrency transactions with transparent invoicing and export documentation.